Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (101-110 of 436) with videos related to

Pageof 44
Sort By:
Journal of Thrombosis and Thrombolysis|November 12, 2013
The unmet need for philanthropic funding of early career cardiovascular investigatorsTariq Ahmad, Richard C Becker
Journal of Thrombosis and Thrombolysis|September 2, 2015
Aspirin dosing in cardiovascular disease prevention and management: an updateLeila Ganjehei, Richard C Becker
Journal of Thrombosis and Thrombolysis|March 9, 2021
Medical publishing during the COVID-19 pandemic: then and nowRichard C Becker, Christoph Bode
Drug Discovery Today|July 8, 2014
Factor IXa as a target for anticoagulation in thrombotic disorders and conditionsDia A Smiley, Richard C Becker
Frontiers in Medicine|December 5, 2024
Bridging the gap: strategies for recognizing and managing post-COVID conditionsMuhammad H Khan, Richard C Becker
Current Atherosclerosis Reports|October 9, 2025
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal TranslationHusam Abu-Nejim, Richard C Becker
Journal of the American College of Cardiology|June 25, 2003
Circadian variations in acute myocardial infarction: patients or health care delivery?Frederick A Spencer, Richard C Becker
American Heart Journal|December 9, 2003
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studiesRobert J Kim, Richard C Becker
Thrombosis and Haemostasis|February 6, 2010
Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapiesRichard C Becker, Paul A Gurbel
Circulation|November 30, 2006
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapyKenneth W Mahaffey, Richard C Becker
Pageof 44

Showing results (101-110 of 436) with videos related to

Sort By:
Pageof 44
Journal of Thrombosis and Thrombolysis|November 12, 2013
The unmet need for philanthropic funding of early career cardiovascular investigatorsTariq Ahmad, Richard C Becker
Journal of Thrombosis and Thrombolysis|September 2, 2015
Aspirin dosing in cardiovascular disease prevention and management: an updateLeila Ganjehei, Richard C Becker
Journal of Thrombosis and Thrombolysis|March 9, 2021
Medical publishing during the COVID-19 pandemic: then and nowRichard C Becker, Christoph Bode
Drug Discovery Today|July 8, 2014
Factor IXa as a target for anticoagulation in thrombotic disorders and conditionsDia A Smiley, Richard C Becker
Frontiers in Medicine|December 5, 2024
Bridging the gap: strategies for recognizing and managing post-COVID conditionsMuhammad H Khan, Richard C Becker
Current Atherosclerosis Reports|October 9, 2025
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal TranslationHusam Abu-Nejim, Richard C Becker
Journal of the American College of Cardiology|June 25, 2003
Circadian variations in acute myocardial infarction: patients or health care delivery?Frederick A Spencer, Richard C Becker
American Heart Journal|December 9, 2003
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studiesRobert J Kim, Richard C Becker
Thrombosis and Haemostasis|February 6, 2010
Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapiesRichard C Becker, Paul A Gurbel
Circulation|November 30, 2006
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapyKenneth W Mahaffey, Richard C Becker
Pageof 44